CARLSBAD, Calif., May 4 /PRNewswire/ -- GenVault Corporation is delighted to welcome Mr. Shane Lyons as Vice President of Sales and Marketing. With over 25 years of experience, Mr. Lyons has achieved an impressive track record of driving sales growth in both the domestic and international life science and clinical marketplaces.
Most recently Mr. Lyons held the position of Vice President of Sales, Americas, for the Protein and Small Molecule Division of Life Technologies (formerly Applied Biosystems, AB), where he managed the sales organization and formulated the strategy for expansion and growth of their Mass Spec business unit. During his time at AB, Mr. Lyons helped lead the Mass Spec business from a number 3 position in the market to the number 1 position. Also during his 10 year tenure at Applied Biosystems, he managed the North America sales organization for all AB businesses including genomics and molecular biology, informatics and mass spectrometry. Before joining AB, Mr. Lyons managed regional sales forces at PerSeptive Biosystems, Abbott Labs, Unipath/Unilever, and Coulter Electronics (Beckman). Mr. Lyons holds a bachelor of science degree in Marketing (minor in Finance) from
"Shane brings a tremendous depth of commercial experience and knowledge in the life sciences market to GenVault, together with proven sales leadership that has demonstrated significant success in our marketplace," said David Wellis, GenVault's President and CEO. "Shane is a wonderful addition to our senior management team and a real advantage to GenVault."
"I am thrilled at the prospect of joining the GenVault management team at such an important stage of the company's development. With my experience in the market and the growth dynamics and challenges facing the Life Sciences arena today, I believe that GenVault has the products and organization to make a significant impact in the way DNA, blood and RNA is transported, managed and stored for testing and research. I believe these products will make a real impact in the way business is conducted in the future," said Mr. Lyons.
A major focus for Genvault's innovative technology platforms is the risk free transportation and high density storage of samples utilized in biobanking. The falling cost of genomic technologies has expanded the scope of biobanking in the contexts of sample volumes analyzed and the spectrum of research studies that can be addressed. The results of several new diagnostic tests which improve risk assessment and treatment decisions being made in the clinic are based on data derived from biobanks. Analysis of high quality samples from large cohorts derived from biobanks will generate new diagnostic and preventative tools for diseases that will define the future of personalized medicine.
GenVault is the global leader in providing risk free biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification. Today, GenVault is empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement agencies to more fully leverage the rapidly growing genomics industry. As a scalable, reliable and environmentally friendly alternative to traditional freezers and DNA purification systems, the company's dry-state platform enables the extraction, preservation, recovery, and distribution of DNA at room temperature. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. From GenPlate to the Dynamic Archive, GenVault is continuously developing and refining best practices for DNA sample management and preservation. For more information visit GenVault at www.genvault.com.
Available Topic Expert: For information on the listed expert, click appropriate link.
Editorial Contact Bret Dash, Director of Marketing GenVault Corporation (760) 268-5242
|SOURCE GenVault Corporation|
Copyright©2009 PR Newswire.
All rights reserved